Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.
1. A method for treating acute kidney injury comprising:
(a) obtaining a urine sample from a subject determined to have sepsis;
(b) performing a first assay to measure a level or concentration of insulin-like growth factor-binding protein 7 in the urine sample and performing a second assay to measure a level or concentration of metalloproteinase inhibitor 2 in the urine sample;
(c) calculating a composite value comprising the level or concentration of insulin-like growth factor-binding protein 7 and the level or concentration of metalloproteinase inhibitor 2;
(d) comparing the composite value of (c) to a first predetermined threshold, wherein the first predetermined threshold comprises a predetermined level or concentration of urinary insulin-like growth factor-binding protein 7 and a predetermined level or concentration of urinary metalloproteinase inhibitor 2;
(e) identifying a subject at risk for occurrence of RIFLE I or F within 24 hours of the time at which the urine sample is obtained from the subject when the composite value is higher as compared to the first predetermined threshold; and
(f) treating the identified subject of (e), wherein the treating comprises initiating kidney replacement therapy, withdrawing delivery of compounds known to be damaging to the kidney, kidney transplant, or modifying diuretic administration, wherein the insulin-like growth factor-binding protein 7 comprises amino acid residues 27-282 of SEQ ID NO: 1.
2. The method of claim 1 , wherein the level or concentration of urinary insulin-like growth factor-binding protein 7 obtained from the first assay is elevated as compared to a second predetermined threshold, wherein the second predetermined threshold comprises the predetermined level or concentration of urinary insulin-like growth factor-binding protein 7.
3. The method of claim 1 , wherein the level or concentration of urinary metalloproteinase inhibitor 2 obtained from the second assay is elevated as compared to a third predetermined threshold, wherein the third predetermined threshold comprises the predetermined level or concentration of urinary metalloproteinase inhibitor 2.
4. The method of claim 1 , comprising measuring the concentration of the insulin-like growth factor-binding protein 7 and the metalloproteinase inhibitor 2 in the sample.
5. The method of claim 1 , wherein the sepsis is severe sepsis or septic shock.
6. The method of claim 1 , wherein performing a first assay comprises contacting all or a portion of the urine sample with a first binding reagent which specifically binds to the insulin-like growth factor-binding protein 7, and generating a first assay result indicative of the level or concentration of the insulin-like growth factor-binding protein 7, and wherein performing a second assay comprises contacting all or a portion of the urine sample with a second binding reagent which specifically binds to metalloproteinase inhibitor 2, and generating a second assay result indicative of the level or concentration of the metalloproteinase inhibitor 2 to the second binding reagent.
7. The method of claim 1 , wherein the composite value is obtained using a function that combines the level or concentration of insulin-like growth factor-binding protein 7 and the level or concentration of metalloproteinase inhibitor 2 into a single composite value.
8. The method of claim 1 , wherein risk for occurrence of RIFLE I or F acute kidney injury is within 12 hours of the time at which urine sample is obtained.
9. The method of claim 1 , wherein the subject is identified at risk for occurrence of RIFLE I within 24 hours of the time at which the urine sample is obtained from the subject.
10. The method of claim 1 , wherein the subject is identified at risk for occurrence of RIFLE F within 24 hours of the time at which the urine sample is obtained from the subject.
11. The method of claim 1 , wherein the subject has suffered from an injury to kidney function, reduced kidney function, or acute kidney failure.
12. The method of claim 1 , wherein the subject is in RIFLE stage R.
13. A method for treating acute kidney injury comprising:
(a) obtaining a urine sample from a subject determined to have sepsis;
(b) measuring a level or concentration of insulin-like growth factor-binding protein 7 in the sample as compared to a first predetermined threshold, wherein the insulin-like growth factor-binding protein 7 comprises amino acid residues 27-282 of SEQ ID NO: 1, wherein the first predetermined threshold comprises a predetermined level of concentration of urinary insulin-like growth factor-binding protein 7;
(c) measuring a level or concentration of metalloproteinase inhibitor 2 in the sample as compared to a second predetermined threshold, wherein the metalloproteinase inhibitor 2 comprises amino acid residues 27-220 of SEQ ID NO: 3, wherein the second predetermined threshold comprises a predetermined level or concentration of the metalloproteinase inhibitor 2;
(d) identifying the subject at risk for occurrence of RIFLE I or F within 24 hours of the time at which the urine sample is obtained from the subject when the level of insulin-like growth factor-binding protein 7 in the sample is elevated as compared to the first predetermined threshold and the level of metalloproteinase inhibitor 2 in the sample is elevated as compared to the second predetermined threshold; and
(e) treating the identified subject of (e), wherein the treating comprises initiating kidney replacement therapy, withdrawing delivery of compounds known to be damaging to the kidney, kidney transplant, or modifying diuretic administration.
14. The method of claim 13 , comprising measuring the concentration of insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 in the sample.
15. The method of claim 13 , wherein sepsis is severe sepsis or septic shock.
16. The method of claim 13 , wherein measuring the level or concentration of insulin-like growth factor-binding protein 7 comprises contacting all or a portion of the urine sample with a first binding reagent which specifically binds to the insulin-like growth factor-binding protein 7, and generating a first assay result indicative of the level or concentration the insulin-like growth factor-binding protein 7, and wherein measuring the level or concentration of metalloproteinase inhibitor 2 comprises contacting all or a portion of the urine sample with a second binding reagent which specifically binds to metalloproteinase inhibitor 2, and generating a second assay result indicative of the level or concentration of the metalloproteinase inhibitor 2 to the second binding reagent.
17. The method of claim 16 , further comprising combining the first and second assay result using a function that converts the first and second assay result into a single combined assay result.
18. The method of claim 13 , wherein the risk for occurrence of RIFLE I or F acute kidney injury is within 12 hours of the time at which urine sample is obtained.
19. The method of claim 1 , wherein the metalloproteinase inhibitor 2 comprises amino acid residues 27-220 of SEQ ID NO: 3.
20. The method of claim 1 , wherein the insulin-like growth factor-binding protein 7 consists of amino acid residues 27-282 of SEQ ID NO: 1.
21. The method of claim 20 , wherein the metalloproteinase inhibitor 2 consists of amino acid residues 27-220 of SEQ ID NO: 3.